ストックスクリーナーアプリを入手
1.15
0.87%
0.0099
アフターアワーズ：
1.15
前日終値:
$1.1401
開ける：
$1.13
24時間の取引高:
85,206
Relative Volume:
0.39
時価総額：
$94.20M
収益：
-
当期純損益:
$-21.65M
株価収益率:
-3.4628
EPS:
-0.3321
ネットキャッシュフロー:
$-15.84M
1週間 パフォーマンス:
+0.88%
1か月 パフォーマンス:
+25.68%
6か月 パフォーマンス:
-42.21%
1年 パフォーマンス:
-47.96%
1日の値動き範囲:
$1.11
$1.1569
1週間の範囲:
$1.05
$1.1696
52週間の値動き範囲:
$0.7709
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
CRDL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.15 | 94.20M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-26 | 開始されました | ROTH MKM | Buy |
| 2024-04-22 | 開始されました | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc (CRDL) 最新ニュース
(CRDL) Advanced Trading Insights (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Rating of “Buy” by Analysts - Defense World
Envestnet Asset Management Inc. Makes New Investment in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
(CRDL) Market Insights and Trading Signals (CRDL:CA) - news.stocktradersdaily.com
Lodgement of CONNEQT Pulse Device with the TGA - Investing News Network
(CRDL) Trading Performance and Risk Management (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Daily Stock Insights (CRDL:CA) - news.stocktradersdaily.com
March Quarterly Activities Report - Investing News Network
March Quarterly Appendix 4C - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Trading Up 6.7% – What’s Next? - Defense World
Profound Medical Corp. - Baystreet.ca
Cardiol Therapeutics Inc. - Baystreet.ca
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors | CRDL Stock News - GuruFocus
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Board Amid Phase III Trial Progress - TipRanks
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors - Newsfile
Cardiol Therapeutics announces annual shareholder meeting By Investing.com - Investing.com India
Cardiol Therapeutics announces annual shareholder meeting - Investing.com
Cardiol Therapeutics Schedules Virtual Annual General Meeting for May 2025 - TipRanks
First patient dosed in Phase IIb imaging for Brain Mets - Investing News Network
(CRDL) Strategic Market Analysis (CRDL:CA) - news.stocktradersdaily.com
A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David ElsleyCardiol Therapeutics - thedeepdive.ca
Long Term Trading Analysis for (CRDL) (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Risk-Controlled Trading Report (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? - Nasdaq
Genocea Biosciences (NASDAQ:GNCA) versus Cardiol Therapeutics (NASDAQ:CRDL) Head-To-Head Review - Defense World
(CRDL) Investment Analysis and Advice (CRDL:CA) - news.stocktradersdaily.com
Roth Capital Has Bearish Forecast for CRDL Q1 Earnings - Defense World
Cardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on Monday - Defense World
Cardiol Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (NASDAQ:CRDL) Earns “Buy” Rating from HC Wainwright - Defense World
Northwestern University enrols first subject in trial of drug for pericarditis - Yahoo
(CRDL) Pivots Trading Plans and Risk Controls (CRDL:CA) - news.stocktradersdaily.com
ardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics Commences Phase III Trial for CardiolRx™ in Recurrent Pericarditis - TipRanks
Cardiol Therapeutics starts phase III trial for heart drug - Investing.com Australia
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile
3 Reasons to Sell CSV and 1 Stock to Buy Instead - The Globe and Mail
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Cardiol Therapeutics Reports Increased Losses Amid Rising Expenses - TipRanks
HC Wainwright Has Negative Outlook for CRDL FY2025 Earnings - Defense World
H.C. Wainwright maintains $9 target on Cardiol Therapeutics stock By Investing.com - Investing.com UK
Cardiol Therapeutics (NASDAQ:CRDL) Receives “Buy” Rating from HC Wainwright - Defense World
Cardiol Therapeutics (TSE:CRDL) Reaches New 1-Year Low – Should You Sell? - Defense World
Cardiol Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate - Yahoo Finance
Cardiol Therapeutics advances heart disease treatments By Investing.com - Investing.com South Africa
Stocks In Play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics Advances Heart Disease Treatments with Promising Clinical Results - TipRanks
Cardiol Therapeutics advances heart disease treatments - Investing.com
Cardiol Therapeutics Announces Year-End 2024 Update on Operations - Newsfile
Cardiol Therapeutics Inc (CRDL) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
1.62%
大文字化:
|
ボリューム (24 時間):